Show simple item record

AuthorDania, Kattan
AuthorBarsa, Chloe
AuthorMekhijian, Sarin
AuthorShakkour, Zaynab
AuthorJammoul, Maya
AuthorDoumit, Mark
AuthorZabala, Maria Camila Pareja
AuthorDarwiche, Nadine
AuthorEid, Ali H.
AuthorMechref, Yehia
AuthorWang, Kevin K.
Authorde Rivero Vaccari, Juan Pablo
AuthorMunoz Pareja, Jennifer C.
AuthorKobeissy, Firas
Available date2023-01-30T07:10:26Z
Publication Date2023-01-31
Publication NameNeuroscience & Biobehavioral Reviews
Identifierhttp://dx.doi.org/10.1016/j.neubiorev.2022.104969
CitationKattan D, Barsa C, Mekhijian S, et al. Inflammasomes as biomarkers and therapeutic targets in traumatic brain injury and related-neurodegenerative diseases: A comprehensive overview. Neurosci Biobehav Rev. 2023;144:104969. doi:10.1016/j.neubiorev.2022.104969
ISSN01497634
URIhttps://www.sciencedirect.com/science/article/pii/S0149763422004584
URIhttp://hdl.handle.net/10576/39172
AbstractGiven the ambiguity surrounding traumatic brain injury (TBI) pathophysiology and the lack of any Food and Drug Administration (FDA)-approved neurotherapeutic drugs, there is an increasing need to better understand the mechanisms of TBI. Recently, the roles of inflammasomes have been highlighted as both potential therapeutic targets and diagnostic markers in different neurodegenerative disorders. Indeed, inflammasome activation plays a pivotal function in the central nervous system (CNS) response to many neurological conditions, as well as to several neurodegenerative disorders, specifically, TBI. This comprehensive review summarizes and critically discusses the mechanisms that govern the activation and assembly of inflammasome complexes and the major methods used to study inflammasome activation in TBI and its implication for other neurodegenerative disorders. Also, we will review how inflammasome activation is critical in CNS homeostasis and pathogenesis, and how it can impact chronic TBI sequalae and increase the risk of developing neurodegenerative diseases. Additionally, we discuss the recent updates on inflammasome-related biomarkers and the potential to utilize inflammasomes as putative therapeutic targets that hold the potential to better diagnose and treat subjects with TBI.
SponsorThis work is partially supported by the grant "UL1TR002736, Miami Clinical, and Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities" (PI: J C. Munoz Pareja). Additionally, this work was also supported by grants from NIH for (PI: Yehia Mechref) (1R01GM112490-09, 1U01CA225753-05, and 1R01GM130091-04) and for (PI: JPdRV) (1R01NS113969-01, 1RF1NS125578-01).
Languageen
PublisherElsevier
SubjectInflammasomes
Traumatic brain injury
Neurodegenerative diseases
Caspase-1
Pyroptosis
Biomarkers
Therapeutic targets
NLPR1
TitleInflammasomes as biomarkers and therapeutic targets in traumatic brain injury and related-neurodegenerative diseases: A comprehensive overview
TypeArticle
Volume Number144
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record